Pidilizumab (CT-011) is a humanized monoclonal antibody (mAb) that modulates the immune response and inhibits tumor growth and the spread of metastases. Mechanistically, pidilizumab activity leads to extended survival of lymphocytes, primarily effector/memory T cells. Pidilizumab also augments anti-tumor activities of NK cells. The enhanced activities of T and NK cells are translated into the intensification of anti-tumor immune response and the generation of tumor-specific memory cells. Pidilizumab is being developed as a treatment for hematological malignancies and solid tumors.
Phase II clinical studies have demonstrated the safety and efficacy of pidilizumab in diffuse large B cell lymphoma (DLBCL), follicular lymphoma as well as in DIPG, a rare form of pediatric brain cancer. Additional studies are ongoing in multiple myeloma and DLBCL.